Regulation - Avastin

Filter

Current filters:

Avastin

Popular Filters

1 to 25 of 28 results

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

13-11-2014

The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs…

AvastinKadcylaOncologyPharmaceuticalRegulationSprycelUK

French regulator requests information from Roche on off-label use of Avastin for wet-AMD

French regulator requests information from Roche on off-label use of Avastin for wet-AMD

07-11-2014

The French pharma regulator, l’Agence nationale de sécurité du médicament et des produits de santé…

AvastinFranceOphthalmicsPharmaceuticalRegulationRoche

Roche’s Avastin gets FDA approval for use with chemotherapy in cervical cancer

Roche’s Avastin gets FDA approval for use with chemotherapy in cervical cancer

15-08-2014

Swiss drug major Roche has received approval from the US Food and Drug Administration for its drug Avastin…

AvastinCervical cancerOncologyPharmaceuticalRegulationRocheSwitzerland

EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer

EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer

06-08-2014

The European Commission has approved the use of Swiss pharma major Roche’s blockbuster cancer drug…

AvastinEuropeOncologyPharmaceuticalRegulationRocheTreatment for women with recurrent ovarian cancer

EUCOPE slams French plans to cut spending through off-label drugs

EUCOPE slams French plans to cut spending through off-label drugs

12-07-2014

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) says it is very concerned about legislative…

AvastinEuropeFranceLegalOphthalmicsPharmaceuticalRegulationRoche

France adopts draft law on off-label use of drugs

France adopts draft law on off-label use of drugs

09-07-2014

The French National Assembly yesterday voted on the draft law proposal, which would potentially allow…

AvastinDraft law proposalEuropeFranceLegalOphthalmicsPharmaceuticalRegulationRoche

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Study reveals factors supporting a sustainable European biosimilar medicines market

Study reveals factors supporting a sustainable European biosimilar medicines market

13-06-2014

Biosimilar medicines will deliver an opportunity for increased access to better healthcare for patients…

AvastinBiosimilarsEuropeHealthcareHerceptinHumiraRegulation

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

Should medical compendia hold so much power? Asks GlobalData

10-04-2013

Guidelines for off-label drug use hold immense commercial implications, and stricter controls are needed…

AvastinBiotechnologyNorth AmericaOncologyPharmaceuticalRegulation

UK's NICE draft guidance says "no" to Roche's Avastin for ovarian cancer

25-03-2013

New, draft guidance issued today (March 25) by the UK's drugs watchdog the National Institute for Health…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

UK's NICE says Roche's Avastin not cost effective for advanced ovarian cancer

18-12-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

New Zealand's PHARMAC decisions on Roche products

11-10-2012

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for…

Asia-PacificAvastinHypnovelMabTheraPharmaceuticalPricingRegulationRocheValcyte

Chugai files of Japanese approval of Avastin for ovarian cancer

11-10-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

Asia-PacificAvastinChugai PharmaceuticalOncologyPharmaceuticalRegulationRoche

Chugai pushed into filing for Avastin glioblastoma indication in Japan

21-09-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

Asia-PacificAvastinChugai PharmaceuticalOncologyPharmaceuticalRegulationRoche

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

NICE draft guidance continues negative on Roche's Avastin for metastatic breast cancer

06-07-2012

Final draft guidance published today (July 6) by the UK's drugs watchdog the National Institute for Health…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

Fake Avastin reignites "Track-and-Trace" debate, but the clock is ticking

14-06-2012

The US Food and Drug Administration announced in February that counterfeit vials of Roche/Genentech's…

AvastinLegalNorth AmericaPharmaceuticalRegulationRoche

NICE turns down Roche breast cancer drug Avastin, citing too many uncertainties

18-04-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE), said this morning…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

1 to 25 of 28 results

Back to top